- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2016
- 2015
October 15, 2024
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting® 2024, Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801)
September 30, 2024
HighTide Therapeutics to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
September 19, 2024
8th Annual MASH Drug Development Summit | HighTide Therapeutics Presents Rationales for Holistic Approaches to Treating MASH and Benefits of Berberine Ursodeoxycholate (HTD1801)
September 10, 2024
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801)
August 29, 2024
HighTide Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
June 21, 2024
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)
June 4, 2024
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)
May 14, 2024
HighTide Therapeutics Invited to Present at the Abu Dhabi Global Healthcare Week Health Leaders Forum
December 8, 2023
HighTide Therapeutics is Invited to Present at the FII PRIORITY Asia Summit in Hong Kong: Megatrends Shaping Humanity
November 2, 2023
HighTide Therapeutics Launches Clinical Trial in Hong Kong: Dosing of First Patient in Ongoing Phase 2b Trial of Berberine Ursodeoxycholate (HTD1801) to Treat NASH
October 25, 2023
HighTide Therapeutics is Invited to Present at the 7th Edition of the Future Investment Initiative (FII): The New Compass, in Riyadh, Saudi Arabia
October 20, 2023
HighTide Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
October 11, 2023
HighTide Therapeutics to Present Data on Improvements in Liver Fat Content and Fibroinflammation Based on MRI Response in Patients with NASH and T2DM treated with Berberine Ursodeoxycholate (HTD1801) at The Liver Meeting® 2023
October 5, 2023
HighTide is Acknowledged by the HK Government as Strategic Enterprise Partner and has been Invited to the OASES Partnership Launch Ceremony
October 3, 2023
HighTide Announces Oral Presentation for Phase 2 Data at the 59th EASD Annual Meeting on Improvements in Glycemic Control with Berberine Ursodeoxycholate (HTD1801), being evaluated for the Treatment of T2DM
July 17, 2023
Chinese Chamber of Commerce Visits HighTide Therapeutics and Successfully Holds a Symposium
June 24, 2023
HighTide Therapeutics Presents Data on the Improvement of Liver Fibroinflammation in Patients with NASH and T2DM at EASL Congress 2023
May 15, 2023
HighTide Therapeutics Announces Phase 2 Study in Type 2 Diabetes (T2DM) Achieves Primary and Important Secondary Endpoints
March 16, 2023
Dr. Liping Liu Selected for the EY Entrepreneurial Winning Women™ Asia-Pacific Class of 2023
February 6, 2023
HighTide Therapeutics Announces Principal Investigator Meeting for NASH Phase 2b Clinical Study (the CENTRICITY study)
February 1, 2023
HighTide Therapeutics Appoints Dr. Tianwei Ma as VP of Discovery Research
February 1, 2023
HighTide Therapeutics Appoints Edmund Sim as Chief Financial Officer
January 11, 2023
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
January 5, 2023
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
November 16, 2022
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics’ Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis
October 24, 2022
HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022
October 20, 2022
HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development
October 14, 2022
HighTide Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
April 28, 2022
HighTide Therapeutics Announces First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus
March 31, 2022
HighTide Therapeutics Appoints Myleen Leoncavallo as SVP Regulatory Affairs and Quality Assurance
February 22, 2022
HighTide Therapeutics Announces End-of-Phase 2 Meeting with FDA and Agreement to Proceed to Phase 3 for HTD1801 for the Treatment of PSC
January 6, 2022
HighTide Therapeutics Appoints Jin Chen, Ph.D., as SVP DMPK and Clinical Pharmacology
October 28, 2021
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
September 21, 2021
HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients
September 10, 2021
HighTide Therapeutics Started Clinical Trial in China
June 22, 2021
HighTide Therapeutics Announces The Presentation of Topline Results of Phase 2 Study of HTD1801 in PSC Patients at the International Liver Congress 2021
June 2, 2021
HighTide Announces First Patient Dosed in Phase 2 PRONTO-PBC Clinical Study Evaluating HTD1801 in Adult Patients with Primary Biliary Cholangitis
May 26, 2021
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
April 28, 2021
HighTide to Present at the BofA Securities 2021 Health Care Conference
March 3, 2021
HighTide to Present at the NASH-TAG 2021 Conference
March 1, 2021
HighTide to Present at the H.C. Wainwright Global Life Sciences Conference
February 1, 2021
HighTide Therapeutics Appoints Dr. Leigh MacConell as Chief Development Officer
December 21, 2020
HighTide Therapeutics to Present Phase 2 Results of HTD1801 in NASH Patients Co-Morbid with Type 2 Diabetes at NASH Summit
October 1, 2020
HighTide Therapeutics to Present at HC Wainwright’s 4th Annual NASH Investor Conference
May 19, 2020
HighTide Therapeutics Will Be Featured During Chardan Leadership Call
May 7, 2020
HighTide Therapeutics Announces Positive Topline Results From Phase 2a Study of HTD1801 in NASH Patients
November 19, 2019
HighTide Therapeutics Announces Regulatory Approvals For Expanded Clinical Development of HTD1801
October 10, 2019
Data to be Presented at AASLD 2019 Shows HighTide Lead Compound Improves NASH in Two Animal Models
October 10, 2019
HighTide Therapeutics and Silexon Tech Have Formed a Long-term Strategic Partnership
September 2, 2019
HighTide Therapeutics Announces DMC Approval to Continue with Phase 2a NASH Study of HTD1801
July 10, 2019
HighTide Therapeutics Joins JLABS at Shanghai
July 2, 2019
HighTide Therapeutics Expands Leadership Team with Appointment of Adrian M. Di Bisceglie, M.D., as Chief Medical Officer
June 4, 2019
HighTide Therapeutics Sponsors PSC Partners Seeking a Cure’s Annual Conference
June 2, 2019
HighTide Therapeutics Invited to Present at HKEX Biotech Week 2019
May 11, 2019
HighTide Therapeutics to Deliver Two Presentations at Phar-East 2019 in Singapore
April 4, 2019
HighTide Therapeutics invited to present at the World Orphan Drug Congress USA 2019
December 11, 2018
HighTide Therapeutics to Present at Biotech Showcase™ 2019 in San Francisco
November 27, 2018
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Nonalcoholic Steatohepatitis (NASH)
October 3, 2018
HighTide Therapeutics Presented at the 2nd Annual Pediatric Autoimmune Liver Disease Symposium and Family Day
September 27, 2018
HighTide Therapeutics Receives Fast Track Designation from the U.S. FDA for HTD1801 Treating Primary Sclerosing Cholangitis
March 20, 2018
Presentation at 25th Annual Future Leaders in the Biotech Industry
March 1, 2018
HighTide’s Drug Candidate, HTD1801, Awarded 2017 National Science and Technology Major Project
December 27, 2016
HTD4010 Project Ends Phase I Clinical Trials in Australia and Tests Expectations
July 22, 2015
HTD4010 Receives Record from Australian Drug